AN2 Therapeutics Files 8-K Report
Ticker: ANTX · Form: 8-K · Filed: May 1, 2025 · CIK: 1880438
| Field | Detail |
|---|---|
| Company | An2 Therapeutics, Inc. (ANTX) |
| Form Type | 8-K |
| Filed Date | May 1, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, financial-statements
TL;DR
AN2 Therapeutics filed a routine 8-K, mostly standard financial disclosures.
AI Summary
On May 1, 2025, AN2 Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material events or disclosures detailed in the provided text beyond the standard reporting requirements.
Why It Matters
This filing indicates AN2 Therapeutics is meeting its regulatory reporting obligations, which is standard for publicly traded companies.
Risk Assessment
Risk Level: low — The filing appears to be a routine disclosure without any new material information that would significantly impact the company's risk profile.
Key Players & Entities
- AN2 Therapeutics, Inc. (company) — Registrant
- May 1, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 001-41331 (identifier) — Commission File Number
- 82-0606654 (identifier) — IRS Employer Identification No.
- 1800 El Camino Real, Suite D (address) — Principal Executive Offices
- Menlo Park, California (location) — Principal Executive Offices City and State
- 94027 (zip_code) — Principal Executive Offices Zip Code
- (650) 331-9090 (phone_number) — Registrant's Telephone Number
FAQ
What is the primary purpose of this 8-K filing for AN2 Therapeutics, Inc.?
The filing is a Current Report on Form 8-K, primarily indicating the submission of financial statements and exhibits as of May 1, 2025.
When was the earliest event reported in this filing?
The earliest event reported is dated May 1, 2025.
In which U.S. state is AN2 Therapeutics, Inc. incorporated?
AN2 Therapeutics, Inc. is incorporated in Delaware.
What is the principal executive office address for AN2 Therapeutics, Inc.?
The principal executive offices are located at 1800 El Camino Real, Suite D, Menlo Park, California, 94027.
Does this filing disclose any new material events or specific financial results for AN2 Therapeutics, Inc.?
Based on the provided text, this filing appears to be a routine disclosure of financial statements and exhibits, and does not detail any new material events or specific financial results.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 1, 2025 regarding AN2 Therapeutics, Inc. (ANTX).